Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

90.69USD
15 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$90.69
Open
--
Day's High
--
Day's Low
--
Volume
25
Avg. Vol
2,787,207
52-wk High
$96.95
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Prothena Corporation Q4 Loss Per Share $0.56
Thursday, 14 Feb 2019 

Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $0.56.Q4 EARNINGS PER SHARE ESTIMATE $-0.94 -- REFINITIV IBES DATA.EXPECTS FULL YEAR 2019 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $64 MILLION TO $72 MILLION.QUARTER-END CASH AND RESTRICTED CASH POSITION OF $431.7 MILLION PROVIDES FUNDING TO ADVANCE NEUROSCIENCE PIPELINE.ENTERED INTO GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE.  Full Article

Celgene Q4 Earnings Per Share $1.50
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Celgene Corp ::CELGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 REVENUE $4.037 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.99 BILLION.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $2.32 -- REFINITIV IBES DATA.REAFFIRMING 2020 FINANCIAL OUTLOOK.REVLIMID SALES FOR Q4 INCREASED 16 PERCENT TO $2,549 MILLION.OZANIMOD U.S. AND EU REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.OTEZLA SALES IN Q4 WERE $448 MILLION, A 21 PERCENT INCREASE YEAR-OVER-YEAR.QTRLY ADJUSTED EARNINGS PER SHARE $2.39.BRISTOL-MYERS SQUIBB AND CELGENE EXPECT TO CLOSE TRANSACTION IN Q3 OF 2019.SEES 2019 GAAP DILUTED EPS $8.40 TO $9.08.2019 GUIDANCE FOR TOTAL REVENUE AND NET PRODUCT SALES OF REVLIMID & OTEZLA UNCHANGED FROM GUIDANCE PROVIDED ON JAN. 7.FY2019 EARNINGS PER SHARE VIEW $10.42, REVENUE VIEW $17.00 BILLION -- REFINITIV IBES DATA.  Full Article

Triphase Accelerator - Entered into new strategic partnership with Celgene Corp
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Celgene Corp ::TRIPHASE ACCELERATOR - ENTERED INTO NEW STRATEGIC PARTNERSHIP WITH CELGENE CORPORATION.TRIPHASE ACCELERATOR - FOCUS OF COLLABORATION TO BE ON PRE-CLINICAL THERAPEUTIC BY OICR FOR LEUKEMIA & OTHER BLOOD CANCERS, SPECIFICALLY TARGETING WDR5 PROTEIN.TRIPHASE ACCELERATOR- CELGENE TO PAY UPFRONT AMOUNT OF $40 MILLION.  Full Article

Facit And Triphase Accelerator Announce New Partnership With Celgene
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Celgene Corp ::FACIT AND TRIPHASE ACCELERATOR ANNOUNCE NEW PARTNERSHIP WITH CELGENE FOR WDR5 LEUKEMIA THERAPY.TRIPHASE ACCELERATOR - CELGENE HAS OPTION TO ACQUIRE TRPH-395 FROM TRIPHASE ACCELERATOR.TRIPHASE ACCELERATOR - CELGENE TO PAY UPFRONT OF $40 MILLION, UPON EXERCISE OF OPTION, CELGENE TO PAY UP TO $940M IN CONTINGENT DEVELOPMENT, MILESTONES.TRIPHASE ACCELERATOR - ADDITIONAL PAYMENTS FROM CELGENE FOR SALES-BASED ROYALTIES ARE ALSO POSSIBLE.  Full Article

Bristol-Myers Says After Celgene Deal Sees More Than $50 Bln In 2025 Revenue
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL MYERS SAYS AFTER CELGENE DEAL SEES MORE THAN $50 BILLION IN 2025 REVENUE , MORE THAN $20 BILLION IN 2025 EARNINGS-SLIDE.  Full Article

Kyn Therapeutics Enters Into Global Strategic Collaboration With Celgene
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Celgene Corp ::KYN THERAPEUTICS ENTERS INTO GLOBAL STRATEGIC COLLABORATION WITH CELGENE TO DEVELOP IMMUNO-ONCOLOGY THERAPIES.KYN THERAPEUTICS - TO GET $80 MILLION UPFRONT PAYMENT, EQUITY INVESTMENT BY CELGENE WITH CLINICAL, REGULATORY MILESTONE PAYMENTS.KYN THERAPEUTICS - CELGENE GAINS EXCLUSIVE OPTIONS TO TWO KYN THERAPEUTIC PROGRAMS.KYN THERAPEUTICS SAYS KYN IS ELIGIBLE FOR SUBSTANTIAL CLINICAL, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.KYN THERAPEUTICS SAYS WILL ALSO RECEIVE TIERED ROYALTIES ON WORLDWIDE NET SALES ON PRODUCTS RESULTING FROM DEVELOPMENT OF LICENSED PROGRAMS..KYN THERAPEUTICS SAYS WILL RECEIVE EQUITY INVESTMENT FROM CELGENE FOR EXCLUSIVE OPTIONS TO GLOBALLY LICENSE KYNASE AND AHR ANTAGONIST PROGRAMS.  Full Article

Celgene CEO Mark Alles Says Drug Pricing Is Coming Down Year-On-Year On A Net Basis - CNBC Interview
Monday, 7 Jan 2019 

Jan 7 (Reuters) - :CELGENE CEO MARK ALLES SAYS DRUG PRICING IS COMING DOWN YEAR-ON-YEAR ON A NET BASIS - CNBC INTERVIEW.CELGENE CEO ALLES SAYS FOURTH QUARTER WOULD BE A RECORD QUARTER FOR COMPANY.  Full Article

Celgene Corp Sees FY 2019 Adj EPS Of $10.60 To $10.80
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Celgene Corp ::ORATION ANNOUNCES 2019 FINANCIAL GUIDANCE AND KEY MILESTONES.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $10.60 TO $10.80.SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION.PROVIDES FULL-YEAR 2019 GUIDANCE AND REAFFIRMS 2020 OUTLOOK.PROVIDES FULL-YEAR 2019 GUIDANCE AND REAFFIRMS 2020 OUTLOOK.OZANIMOD REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.FOR FULL-YEAR 2019 TOTAL REVENUE EXPECTED TO BE $17.0 BILLION TO $17.2 BILLION.SEES FY 2019 GAAP EARNINGS PER SHARE $8.48 TO $9.17.FY2019 EARNINGS PER SHARE VIEW $10.37, REVENUE VIEW $16.96 BILLION -- REFINITIV IBES DATA.SEES REVLIMID NET PRODUCT SALES ABOUT $9.7 BILLION IN 2018 AND ABOUT $10.8 BILLION IN 2019.  Full Article

Celgene Corp, Acceleron Pharma Announce Results Of Phase 3 Medalist Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes
Sunday, 2 Dec 2018 

Dec 2 (Reuters) - Celgene Corp ::ORATION AND ACCELERON PHARMA ANNOUNCE RESULTS OF THE PHASE 3 MEDALIST TRIAL EVALUATING LUSPATERCEPT IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AT THE ASH 2018 PLENARY SESSION.REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.MEDALIST MET PRIMARY ENDPOINT OF RED BLOOD CELL TRANSFUSION INDEPENDENCE (RBC-TI) FOR 8 OR MORE WEEKS DURING FIRST 24 WEEKS OF STUDY.  Full Article

FDA Says Symptoms Of Differentiation Syndrome Are Not Being Recognized With Idhifa
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - U.S. Food and Drug Administration::FDA WARNS THAT SYMPTOMS OF A SERIOUS CONDITION AFFECTING THE BLOOD CELLS ARE NOT BEING RECOGNIZED WITH THE LEUKEMIA MEDICINE IDHIFA (ENASIDENIB).FDA - IDHIFA PRESCRIBING INFORMATION AND PATIENT MEDICATION GUIDE ALREADY CONTAIN A WARNING ABOUT DIFFERENTIATION SYNDROME..FDA - BECOME AWARE OF CASES OF DIFFERENTIATION SYNDROME IN PATIENTS RECEIVING IDHIFA NOT BEING RECOGNIZED, PATIENTS NOT RECEIVING NECESSARY TREATMENT.FDA - IDHIFA IS MANUFACTURED FOR AND MARKETED BY CELGENE, LICENSED FROM AGIOS PHARMACEUTICALS.FDA - HEALTH CARE PROFESSIONALS SHOULD ALSO BE VIGILANT IN MONITORING FOR DIFFERENTIATION SYNDROME WHEN PRESCRIBING AGIOS' TIBSOVO.  Full Article

Photo

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.